A5049160943- Multiple Sclerosis Research Studies
- Immunotherapy and Immune Responses
- Peripheral Neuropathies and Disorders
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Monoclonal and Polyclonal Antibodies Research
- Fungal Plant Pathogen Control
- Chronic Lymphocytic Leukemia Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Systems, Economic Evaluations, Quality of Life
- Reproductive System and Pregnancy
- Immune Cell Function and Interaction
- Herpesvirus Infections and Treatments
- Autoimmune Neurological Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Mycobacterium research and diagnosis
- Epilepsy research and treatment
- Advanced Data Storage Technologies
- Ocular Diseases and Behçet’s Syndrome
- Viral Infections and Immunology Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cerebral Venous Sinus Thrombosis
- Immune Response and Inflammation
- Genetic Neurodegenerative Diseases
- Autoimmune and Inflammatory Disorders Research
University of South Florida
2016-2025
Florida College
2016-2024
James A. Haley Veterans' Hospital
2016-2024
Multiple Sclerosis Foundation
2015-2021
Roche (Switzerland)
2020
Central Texas Neurology Consultants
2020
University of British Columbia
2020
Oregon Health & Science University
2020
Territory Neurology & Research Institute
2020
Ibero American University
2018-2019
<h3>Objective</h3> The phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms Multiple Sclerosis (VELOCE) study (NCT02545868) assessed responses selected vaccines ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis. <h3>Methods</h3> Patients were randomized 2:1 into OCR group (n = 68; 600 mg) or control 34; interferon beta no disease-modifying therapy). All received tetanus toxoid (TT)-containing vaccine, Pneumovax...
The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.
To assess functional changes in lymphocyte repertoire and subsequent clinical implications during delayed-release dimethyl fumarate (DMF) treatment patients with multiple sclerosis.Using peripheral blood from several trials of DMF, immune cell subsets were quantified using flow cytometry. For some patients, counts assessed after DMF discontinuation. Incidence adverse events, including serious opportunistic infections, was assessed.In DMF-treated absolute (ALCs) demonstrated a pattern decline...
Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS). Objective: To demonstrate bioequivalence of ofatumumab administered by an autoinjector versus a pre-filled syringe (PFS) and to explore effect on B-cell depletion. Methods: APLIOS (NCT03560739) 12-week, open-label, parallel-group, phase-2 study patients with RMS receiving subcutaneous 20 mg every 4 weeks (q4w) (from Week 4, after initial doses...
Background: Ofatumumab has demonstrated superior efficacy and favorable safety for up to 2.5 years versus teriflunomide in relapsing multiple sclerosis (RMS). Objective: Further characterize of ofatumumab RMS. Methods: Efficacy set: patients randomized ofatumumab/teriflunomide ASCLEPIOS I/II (core). Safety who received ⩾ 1 dose I/II, APLIOS, APOLITOS (all core), or ALITHIOS (umbrella open-label extension). Patients continuous were newly switched from teriflunomide. Data cut-off: 25 September...
Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially, then stabilizes on treatment.PROCLAIM, a 96-week, prospective, open-label, phase 3b study, assessed subsets immunoglobulin (Ig) levels during 48 96 weeks (W) DMF treatment.Patients received 240 mg BID. Endpoints: subset changes (primary); Ig isotypes ALC (secondary); adverse events relationship between ARR/EDSS (exploratory);...
To assess ofatumumab's longer-term safety and efficacy for up to 6 years in people with relapsing multiple sclerosis (pwRMS).
The majority of deep learning models in medical image analysis concentrate on single snapshot timepoint circumstances, such as the identification current pathology a given or volume. This is often contrast to diagnostic methodology radiology where presumed pathologic findings are correlated prior studies and subsequent changes over time. For multiple sclerosis (MS), body literature describes various forms lesion segmentation with few analyzing disability progression purpose longitudinal...
Controversy exists regarding a potential link between exposure to recombinant hepatitis B vaccine (HBV) and central nervous system demyelinating diseases. Here, we present case of seronegative neuromyelitis optica spectrum disorder (NMOSD) following HBV. A 28-year-old man developed painful eye movements 11 days after Within 24 h, he experienced vision loss, ascending numbness, ataxia. T-spine MRI showed cord lesion spanning T6-T9. Brain bilateral optic nerve contrast enhancement right-sided...
Purpose Sexual dysfunction is a common but often overlooked secondary symptom of multiple sclerosis (MS) and can be associated with decreased health-related quality life (HRQoL). Natalizumab disease-modifying therapy approved for the treatment relapsing forms MS. In addition to its efficacy, those using natalizumab have shown improvement in HRQoL parameters, including fatigue cognition. The idea that may also correlate sexual impetus this study. Methods A single-center, open-label,...
To assess ofatumumab's longer-term efficacy for up to 6 years in people with recently diagnosed treatment-naive (RDTN) relapsing multiple sclerosis (RMS).
Migraines are a common comorbidity and source of disability in patients with chronic inflammatory diseases like multiple sclerosis (MS). Recently, therapeutic agents for episodic migraine known as calcitonin gene-related peptide (CGRP) inhibitors have shown to effectively control attacks improve quality life the general population. This study explored use these novel individuals comorbid MS.
Abstract Introduction About 20%–35% of multiple sclerosis (MS) patients fail to respond high‐dose corticosteroids during a relapse. Repository corticotropin injection (RCI, Acthar ® Gel) is naturally sourced complex mixture adrenocorticotropic hormone analogs and pituitary peptides that has anti‐inflammatory immunomodulatory effects. Aims The study objective was determine the efficacy safety RCI in with MS relapse inadequately responded corticosteroids. This multicenter, double‐blind,...
<h3>Objective:</h3> To evaluate compliance and persistence with ofatumumab in patients relapsing multiple sclerosis (RMS) for up to 4 years across the core studies ALITHIOS extension study (NCT03650114). <h3>Background:</h3> In pooled ASCLEPIOS I/II (NCT02792218/NCT02792231) trials, demonstrated superior efficacy a similar safety profile teriflunomide RMS. Sustained consistent were observed open-label years. I/II, 98.8% of had ≥80% on ofatumumab; 82.9% receiving completed treatment 30...